Yelp Slides after 2,000 Complaints in Last Five Years are Revealed; Plug Power Acquires ReliOn for $4M in Stock


Follow this company

Companies Mentioned

NYSE:YELP / NASDAQ:PLUG / NYSE:TWTR / PK:NVLX
04/04/2014 [ACCESSWIRE]

Yelp, Inc. (NYSE: YELP) – For an in-depth report on Yelp, Inc. follow: www.BullTrends.com/stockquote/YELP

Yelp Inc. shares closed down 6.64% on about 8.1 million shares traded. The stock was one of the biggest decliners on the NYSE. The stock dropped after it was revealed that the Federal Trade Commission disclosed yesterday that it had received over 2,000 complaints about the company over the last five years.

Plug Power Inc. (NASDAQ: PLUG) - For an in-depth report on Plug Power Inc. follow: www.BullTrends.com/stockquote/PLUG

Shares of Plug Power closed up 2.01% on about 27.4 million shares traded on Thursday. The company is buying the assets of fuel cell developer ReliOn Inc., based in Spokane, Wash. ReliOn has had AT&T, Sprint and Verizon as customers. The company paid about $4 million in stock, the company said in a statement after market close Wednesday. Other details of the deal were not disclosed.

Twitter, Inc. (NYSE: TWTR) - For an in-depth report on Twitter, Inc. follow: www.BullTrends.com/stockquote/TWTR

Shares of Twitter closed down 3.67% on about 11.1 million shares traded on Thursday. The stock was one of the biggest decliners on the NYSE. The company said that users of its Vine video application can now send their contacts private videos and other messages, stepping up competition with Facebook Inc. in the mobile-messaging market.

Nuvilex, Inc. (OTC: NVLX) – For an in-depth report on Nuvilex, Inc. follow: www.BullTrends.com/stockquote/NVLX

Shares of NVLX closed up 16.23% on about 22.5 million shares traded. The stock was one of the biggest gainers in the OTC market. The company has signed a Master Services Agreement with Translational Drug Development (TD2) pursuant to which TD2 will conduct preclinical and clinical studies in support of the development of Nuvilex's pancreatic cancer and other treatments utilizing Cell-in-a-Box(R) technology.

 

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

COMMENTS

Leave a comment...
 * 

Your Name
 *